Royal DSM is a global, purpose-led company in health and nutrition, applying science to improve the health of people, animals, and the planet. DSM’s purpose is to create brighter lives for all which we achieve through developing products and solutions that address some of the world’s biggest challenges while simultaneously creating economic, environmental, and societal value for all its stakeholders – customers, employees, shareholders, and society-at-large.
Key facts and figures about DSM, our broad, global health and nutrition business, and our people, planet and profit performance.
We routinely publish our financial performance, with more detail at half and full year where we also provide updates on key milestones on our strategic journey.
DSM has celebrated more than three decades since its privatisation and our ordinary shares being listed on the Euronext Stock Exchange in Amsterdam, the Netherlands.
DSM’s continuing operations are organized around three business groups, each with clear opportunities to benefit the health of people and the health of the planet which underpin DSM’s growth plans.
Food & Beverage (F&B) combines food, beverage, and pet food activities. This business group is uniquely able to meet the needs of customers and consumers by developing sustainable taste, texture, and health solutions. The business group’s portfolio includes breakthrough innovations such as EVERSWEET™, a natural calorie-free sweetener, and CanolaPRO®, a plant-based alternative protein.
Health, Nutrition & Care (HNC) aims to keep the world’s growing population healthy through nutrition and care. This business group provides unique, sustainable, science-based and innovative solutions for consumers in early-life nutrition, dietary supplements, pharma, medical nutrition, personal care, fragrances, and biomedical materials, as well as nutrition improvement for the most vulnerable communities. It includes a rich innovation portfolio including ampli-D®, the rapid-acting and potent form of vitamin D, an extensive algal lipids portfolio, personalized nutrition initiatives such as Hologram Sciences™, as well as human milk oligosaccharide-prebiotics.
Animal Nutrition & Health (ANH) focuses on specialty solutions for a radical transformation in the sustainability of animal protein production. Incorporating essential products such as vitamins, carotenoids, eubiotics and mycotoxin risk management, as well as a wide range of impactful innovations such as methane inhibitor Bovaer® and fish-oil algae-alternative Veramaris®. This business group also includes precision initiatives with data-driven decision-making tools for famers like Sustell™, and for veterinarians and animal health practitioners like Verax™.
30 Dec 2022
Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.
29 Dec 2022
Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.
27 Dec 2022
Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.
Key facts and figures about DSM, our business and our people, planet & profit performance in one overview.
Instant overview of the financial results, presentations, updates & AGMs and all DSM's financial and regulatory press releases from the last decade.
An introduction to DSM's Investor Relations team and how investors and analysts can contact them.
